Bibliography
- AL-OBEIDI FA, LAM KS: Development of inhibitors for protein tyrosine kinases. Oncogene (2000) 19:5690–5701.
- ••A review of the most relevant TKIsdescribed in the literature over the past 5 years.
- LEVITZKI A: Protein tyrosine kinase inhibitors as therapeutic agents. Bioorg. Chem. Biol. Signal Transduction (2001) 211:1–15.
- DUMAS J: Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. The]: Patents (2001) 11(3):405–429.
- NO AUTHORS LISTED: Sugen acquisition would add three anticancer agents to P&U pipeline. Scrip (17 June 1999).
- NO AUTHORS LISTED: Pharmacia drops lead angiogenesis product. Scrip (12 February 2002).
- NO AUTHORS LISTED: Pharmacia's 5U5416 not effective. Exp. Rev Anticancer Ther. (2002) 2(1):5–8.
- SUN L, TRAN N,TANGF, APP H, HIRTH P et al: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. Med. Chem. (1998) 41(14):2588–2603.
- SUN L, TRAN N, LIANG C,TANGF, RICE A et al.: Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. Med. Chem. (1999) 42(25):5120.
- ZHAO YP, YANG CY, HAZNEDAR J, ANTONIAN L: Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS. I Pharm. Biomed Anal. (2001) 25:821–832.
- MENDEL DB, LAIRD AD, XIN XH, LOUIE SG, CHRISTENSEN JG et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327–337.
- MANLEY PW, MARTINY-BARON G, SCHLAEPPI JM, WOOD JM: Therapies directed at vascular endothelial growth factor. Exp. Opin. Investig. Drugs (2002) 11:1715–1736.
- LACKEY K, CORY M, DAVIS R et al.: Thediscovery of potent cRafl kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10(3):223–226.
- BRAMSON HN, CORONA J, DAVIS ST et al.: Oxindole-based inhibitors of cyclin-dependent kinase 2 (Cdk2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. Med. Chem. (2001) 44(25):4339–4358.
- MESTERS PM, PADRO T, BIEKER R, STEINS M, KREUTER M et al.: Stable remission after administration of the receptor tyrosine kinase inhibitor 5U5416 in a patient with refractory acute myeloid leukemia. Blood (2001) 98:241–243.